C. Manegold

2.2k total citations · 1 hit paper
58 papers, 1.6k citations indexed

About

C. Manegold is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, C. Manegold has authored 58 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 38 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in C. Manegold's work include Lung Cancer Treatments and Mutations (32 papers), Lung Cancer Research Studies (19 papers) and Lung Cancer Diagnosis and Treatment (11 papers). C. Manegold is often cited by papers focused on Lung Cancer Treatments and Mutations (32 papers), Lung Cancer Research Studies (19 papers) and Lung Cancer Diagnosis and Treatment (11 papers). C. Manegold collaborates with scholars based in Germany, Italy and France. C. Manegold's co-authors include U. Gatzemeier, Joachim von Pawel, K. Mattson, Alan B. Sandler, L H Einhorn, Martin Palmer, Anne Gregor, Binh Thanh Nguyen, Claude Denham and Clet Niyikiza and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Stroke.

In The Last Decade

C. Manegold

56 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer

2000 606 citations Alan B. Sandler, John Nemunaitis et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Manegold Germany	17	1.1k	1.0k	390	136	127	58	1.6k
Antonio Galvano Italy	24	996 0.9×	800 0.8×	475 1.2×	154 1.1×	540 4.3×	96	1.8k
J. Bonneterre France	9	764 0.7×	462 0.5×	224 0.6×	160 1.2×	464 3.7×	28	1.3k
William J. Edenfield United States	19	783 0.7×	741 0.7×	674 1.7×	143 1.1×	168 1.3×	101	2.1k
Don V. Jackson United States	27	1.3k 1.1×	508 0.5×	337 0.9×	219 1.6×	270 2.1×	75	2.0k
Raffaella Palumbo Italy	20	560 0.5×	474 0.5×	313 0.8×	133 1.0×	160 1.3×	59	1.1k
Rose J. Papac United States	19	647 0.6×	377 0.4×	373 1.0×	342 2.5×	164 1.3×	49	1.5k
Dale R. Shepard United States	17	478 0.4×	470 0.5×	419 1.1×	115 0.8×	258 2.0×	75	1.2k
D. Aubert France	11	1.2k 1.0×	1.8k 1.8×	254 0.7×	181 1.3×	279 2.2×	31	2.2k
G Dabouis France	21	1.5k 1.3×	1.5k 1.5×	450 1.2×	161 1.2×	124 1.0×	69	2.3k
Masaoki Harada Japan	23	289 0.3×	640 0.6×	369 0.9×	284 2.1×	200 1.6×	89	1.6k

Countries citing papers authored by C. Manegold

Since Specialization

Citations

This map shows the geographic impact of C. Manegold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Manegold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Manegold more than expected).

Fields of papers citing papers by C. Manegold

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Manegold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Manegold. The network helps show where C. Manegold may publish in the future.

Co-authorship network of co-authors of C. Manegold

This figure shows the co-authorship network connecting the top 25 collaborators of C. Manegold. A scholar is included among the top collaborators of C. Manegold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Manegold. C. Manegold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Scagliotti, Giorgio V., Cesare Gridelli, Filippo de Marinis, et al.. (2014). Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials. Lung Cancer. 85(3). 408–414. 18 indexed citations

Brodowicz, Thomas, Tudor–Eliade Ciuleanu, Jeffrey Crawford, et al.. (2011). Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. Annals of Oncology. 23(5). 1223–1229. 23 indexed citations

Skillings, Jamey, Natasha B. Leighl, Jaafar Bennouna, et al.. (2007). Safety of Bevacizumab Treatment in Non–Small-Cell Lung Cancer (NSCLC) Subjects Receiving Full-Dose Anticoagulation (FDAC) Treated on Protocol BO17704. Clinical Lung Cancer. 8(7). 454–454. 3 indexed citations

Manegold, C., et al.. (2005). Combination of a Toll-like receptor 9 (TLR9) agonist, CPG 7909 (CPG) with first line taxane/platinum improves response rate in late stage non-small-cell lung cancer (NSCLC). mediaTUM (Technical University of Munich). 2 indexed citations

Gridelli, Cesare, Andrea Ardizzoni, Thierry Le Chevalier, et al.. (2004). Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Annals of Oncology. 15(3). 419–426. 121 indexed citations

Braybrooke, Jeremy, C. Manegold, K. Mattson, et al.. (2003). Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer. Lung Cancer. 41(2). 215–219. 15 indexed citations

Tjan‐Heijnen, Vivianne C. G., Pieter E. Postmus, Andrea Ardizzoni, et al.. (2001). Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study. Annals of Oncology. 12(10). 1359–1368. 79 indexed citations

Manegold, C.. (2001). Chemotherapy for advanced non-small cell lung cancer: standards. Lung Cancer. 34. S165–S170. 28 indexed citations

Sandler, Alan B., John Nemunaitis, Claude Denham, et al.. (2000). Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 18(1). 122–122. 606 indexed citations breakdown →

10.

Rizzoli, R., D. Thiébaud, Nigel Bundred, et al.. (1999). Serum Parathyroid Hormone-Related Protein Levels and Response to Bisphosphonate Treatment in Hypercalcemia of Malignancy. The Journal of Clinical Endocrinology & Metabolism. 84(10). 3545–3550. 32 indexed citations

11.

Thödtmann, R., Andreas Hüttmann, C. Manegold, et al.. (1998). Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion. Investigational New Drugs. 16(4). 319–324. 27 indexed citations

12.

Manegold, C., et al.. (1997). Das diffuse maligne Pleuramesotheliom: Diagnostik, Therapie, Prognose. Oncology Research and Treatment. 20(1). 64–69. 1 indexed citations

13.

Fiebig, H.H., H. Henß, U. Gatzemeier, et al.. (1996). Phase II Clinical Trial of Lobaplatin (D-19466) in Pretreated Patients with Small-Cell Lung Cancer. Oncology Research and Treatment. 19(4). 328–332. 14 indexed citations

14.

Manegold, C., P. Drings, U. Gatzemeier, et al.. (1996). Lobaplatin (D-19466) in Patients with Advanced Non-Small-Cell Lung Cancer: A Trial of the Association for Medical Oncology (AIO) Phase II Study Group. Oncology Research and Treatment. 19(3). 248–251. 7 indexed citations

15.

Mross, K., Andreas Hüttmann, Kenneth D. Herbst, et al.. (1996). Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611 A study by the AIO groups PHASE-I and APOH. Cancer Chemotherapy and Pharmacology. 38(3). 217–224. 16 indexed citations

16.

Pecherstorfer, Martin, Z. Herrmann, Jean‐Jacques Body, et al.. (1996). Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy.. Journal of Clinical Oncology. 14(1). 268–276. 98 indexed citations

17.

Thiébaud, D., C. Manegold, Dorothea Krahl, et al.. (1993). Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia. Bone and Mineral. 22(2). 77–85. 23 indexed citations

18.

Steinke, B., C. Manegold, Mathias Freund, et al.. (1992). G-CSF for Treatment Intensification in High-Grade Malignant Non-Hodgkin’s Lymphomas. Oncology Research and Treatment. 15(1). 46–50. 3 indexed citations

19.

Räth, U., Hans‐Henning Flechtner, C. Manegold, et al.. (1990). Etoposide, Adriamycin, and Cisplatinum (EAP) Combination Chemotherapy for Advanced Gastric Cancer. Oncology Research and Treatment. 13(3). 194–197. 7 indexed citations

20.

Manegold, C., B. Krempien, M. Kaufmann, K. Schwechheimer, & Gotthard Schettler. (1988). The value of bone marrow examination for tumor staging in breast cancer. Journal of Cancer Research and Clinical Oncology. 114(4). 425–428. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact